Literature DB >> 28974898

Detection of metastatic cancer cells in mesentery of colorectal cancer patients.

Xue-Lai Luo1, Da-Xing Xie1, Jian-Xin Wu1, An-Ding Wu1, Zong-Qing Ge1, Hai-Jie Li1, Jun-Bo Hu1, Zhi-Xin Cao1, Jian-Ping Gong2.   

Abstract

AIM: To detect the existence of isolated cancer cells in the mesentery of colorectum (named as Metastasis V), and investigate its clinical significance in colorectal cancer (CRC) patients.
METHODS: Sixty-three CRC patients who received radical excision between January 2012 and September 2015 were included. All the patients underwent laparoscopy-assisted radical colorectomy or proctectomy [with complete mesocolic excision (CME) or total mesorectal excision (TME)] with R0 dissections at the Department of Gastrointestinal Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology. The location and size of the primary lesions were recorded immediately after the tumor was removed, with the surrounding mesenterium completely separated along the intestinal wall. Each dissected mesentery sample was analyzed for hematoxylin-eosin staining and immunohistochemistry using cytokeratin 19 antibody. Image Pro Plus Software 6.0 (Media Cybernetics, CA, United States) was used to semi-quantitatively measure the concentration of the cytokeratin 19 immunohistochemistry. The correlation between metastasis found in mesentery and clinicopathological characteristics was examined. The prognosis of patients was also evaluated by preoperative serum CEA level.
RESULTS: Metastasis V was detected in 14 of 63 (22.2%) CRC patients who underwent laparoscopy-assisted radical colorectomy or proctectomy (with CME or TME) with R0 dissection in our hospital between January 2012 and September 2015. There was no significant difference in age, gender, tumor size, and tumor location in patients with Metastasis V (P > 0.05). Metastasis V was more likely to occur in poorly differentiated tumor (5/11; 45.5%) than moderately (8/46; 17.4%) and well- differentiated one (1/6; 16.7%). The Metastasis V in N2 stage (9/14; 64.3%) was more frequent that in the N0 stage (3/35; 8.6%) or N1 stages (2/14; 14.3%). In addition, Metastasis V was positively related to the tumor invasive depth (T1:0/1, 0%; T2:1/12, 8.3%; T3:7/39, 17.9%; T4:6/11, 54.5%). Furthermore, preoperative serum CEA level in Metastasis V-positive patients was significantly higher than in Metastasis V-negative patients (4.27 ng/mL vs 3.00 ng/mL).
CONCLUSION: Metastasis V might be associated with a poor prognosis of CRC patients.

Entities:  

Keywords:  Colorectal cancer; Colorectal mesentery; Metastasis V; Radical surgery; Serum CEA level

Mesh:

Substances:

Year:  2017        PMID: 28974898      PMCID: PMC5603498          DOI: 10.3748/wjg.v23.i34.6315

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


Core tip: Local-regional recurrence of colorectal cancer (CRC) is common in patients who received R0 resection. Our previous study proposed a novel type of metastasis designated as “Metastasis V” in gastric cancer. Metastasis V is defined as the appearance of cancer cells in the mesentery in broad sense, and may be a risk factor for the poor prognosis after radical surgery. In this study, Metastasis V was also detected in the mesentery of colorectum, and it might be associated with the poor prognosis of CRC patients.

INTRODUCTION

Three decades ago, RJ Heald introduced the total mesorectal excision (TME) in the treatment of rectal cancer[1]. Subsequently, complete mesocolic excision (CME) was popularized by W Hoehenbuerg to reduce tumor relapse and improve prognosis in colon cancer patients[2]. These new approaches greatly contributed to the complete mesentery excision and improved lymph node harvest. Furthermore, with the development of surgical technology, neo-adjuvant chemotherapy and efficient perioperative management, the prognosis of patients with colorectal cancer (CRC) has been improved. However, local-regional recurrence of CRC is still often noted in the patients who received radical R0-resection with no lymphatic metastasis[3]. Direct invasion, lymphatic drainage, hematogenous spread and peritoneal dissemination are the four classical routes for local-regional recurrence or distant implantion of cancer cells. In addition to these pathways, the existence of metastatic cancer cells in the mesentery of colorectum has also been reported, and this type of metastasis was named as “extra-capsular spreads” or “extra-nodal metastasis”[4-7]. In our previous study, we proposed a novel type of tumor metastasis designated as Metastasis V in gastric cancer. Metastasis V is defined as the appearance of cancer cells in the mesogastrium with perigastric adipose tissue, and it may be a risk factor for patient survival after radical surgery[8]. Here, in this study, we further determined whether Metastasis V can be detected in the mesocolorectum, and examined its clinical significance.

MATERIALS AND METHODS

Patients, samples, and sectional tissue analysis

Sixty-three patients who underwent surgery for CRC at the Department of Gastrointestinal Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology between January 2012 and September 2015 were included in this study. The patients consisted of 25 female patients and 38 male patients. All of these patients received laparoscopy-assisted radical colorectomy or proctectomy (with CME or TME) with R0 dissection. All participants signed informed written consents in this research. This study was approved by the Tongji Hospital Ethics Committee. Clinical samples of CRC were obtained from the resected colorectal tissue. The location and size of the primary lesions were recorded immediately after the tumor was removed, and then the mesenterium was completely separated from the intestinal wall along with the anterior edge. All specimens were fixed in 10% formaldehyde before processing. The lymph nodes were obtained from the mesenterium. Next, the mesentery was cut into strip-shape with a width of 2 cm in an outward-to-inward manner, vertical to the intestinal wall. The strip-shaped samples were cut into cube samples with a mean length of 2 cm. All of the small samples were numbered from inside (proximal end of the cancer) to outside (Figure 1). These samples were embedded in 10% formaldehyde. Demographic characteristics of the 63 patients are described in Table 1. The clinicopathological stage was determined by the 7th edition of the AJCC Cancer Staging Manual.
Figure 1

Samples of mesenterium from colorectal cancer patients. Analysis of large cross sectional tissue samples of mesentery of colorectum from surgically resected specimens.

Table 1

Data in 63 colorectal cancer patients

ParametersResults
Gender
Female25
Male38
Age (yr, mean, range)55.5 (28-86)
Location of cancer
Colon11
Rectum52
Differentiated grade
Well6
Moderately46
Poorly11
Affected lymph nodes
N035
N114
N214
Invasive depth
T11
T212
T339
T411
Data in 63 colorectal cancer patients Samples of mesenterium from colorectal cancer patients. Analysis of large cross sectional tissue samples of mesentery of colorectum from surgically resected specimens.

Immunohistochemical analysis of Metastasis V

Immunohistochemistry was performed using the cytokeratin 19 antibody. Cytokeratin 19 is specifically expressed in intestine epithelia cells and CRC cells[9]. Hence, it has been proven to be a highly sensitive marker for CRCs. Immunostaining was performed by the standard streptavidin-biotin method. First, the slices were de-paraffinized and rehydrated. To retrieve antigenicity, the slices were boiled in 0.01 mol/L, pH 6.0 sodium citrate buffer for approximately 15 min. Endogenous peroxidase was restrained with 0.3% hydrogen peroxide for roughly 25 min. After blocking with 3% BSA for 30 min, the anti-cytokeratin 19 monoclonal antibody was arranged in blocking buffers and the slices were incubated at 4 °C overnight. After being washed in pH 7.4 PBS 3 times (5 min each time), the corresponding secondary antibody, retained at room temperature for approximately 50 min and marked by HRP was added. After one more wash with pH 7.4 PBS for 15 min, the chromogenic reagent DAB was added to the colorate. The slices were counterstained with Harris hematoxylin, dehydrated in a graded alcohol series (75% alcohol for 6 min, 85% alcohol for 6 min, absolute ethyl alcohol I for 6 min, and absolute ethyl alcohol II for 6 min), cleared in xylene for 5 min, and mounted. Individual tumor cells in mesenteries, separated from primary lesion and lymph nodes, were identified to be Metastasis V.

Immunohistochemistry image analysis

Image Pro Plus Software 6.0 (Media Cybernetics, CA, United States) was used to semi-quantitatively measure the concentration of the cytokeratin 19 immunohistochemistry. This procedure, was split into six steps: (1) discovering and surveying the section of interest; (2) adjusting the optical densities; (3) obtaining, transforming and preserving images; (4) amending the background and background staining; (5) configuration of the section of interest to determine the optical density; and (6) examining optical densities.

Statistical analysis

The Fisher’s exact test, χ² test, and Mann-Whitney U test were used to inspect the significance of the differences between the covariates. We considered a P value of less than 0.05 statistically significant. Standard statistical analyses were performed by SPSS version 20.0.

RESULTS

Detection of Metastasis V in mesenterium of CRC patients

Metastasis V was detected in 14 of the 63 (22.2%) patients by immunohistochemistry staining. These isolated cancer cells separated from the primary lesion and lymph nodes were observed in the same slice (Figure 2). In terms of “T” stage, only one case showed limited muscular layer invasion, seven cases had sub-serosal invasion, and the rest had serosal invasion. In these patients, there were three lymph node negative patients with different invasive depths (Table 2).
Figure 2

Detection of Metastasis V in colorectal cancer patients. Isolated cancer cells were detected in the mesentery of colorectum by HE staining. A (× 10), B (× 20) and C (× 40) represent the same slide; D (× 10), E (× 20) and F (× 40) represent the same slide.

Table 2

Data in Metastasis V-positive patients

PatientsSexAge (yr)Cancer size (cm)Cancer locationDifferentiated gradeInvasive depthAffected lymph nodesTNM
1F372.5RectumPoorlySerosal8/15pT4N2M0
2F423RectumModeratelySubserosal5/17pT3N2M0
3M332RectumModeratelySerosal5/15pT4N2M0
4M486SigmoidWellSerosal12/21pT4N2M0
5F633RectumPoorlyMuscularis0/15pT2N2M0
6F453RectumModeratelySerosal5/28pT4N2M0
7M583RectumPoorlySubserosal8/12pT3N2M0
8M644RectumPoorlySubserosal7/15pT3N2M1
9M546RectumModeratelySubserosal2/13pT3N1M0
10F602Descending colonModeratelySubserosal0/17pT3NxM0
11M543RectumModeratelySerosal5/12pT4N2M0
12M583RectumModeratelySubserosal0/16pT3N0M0
13F573RectumPoorlySerosal2/21pT4N1M1
14M474RectumModeratelySubserosal24/32pT3N2M0
Data in Metastasis V-positive patients Detection of Metastasis V in colorectal cancer patients. Isolated cancer cells were detected in the mesentery of colorectum by HE staining. A (× 10), B (× 20) and C (× 40) represent the same slide; D (× 10), E (× 20) and F (× 40) represent the same slide.

Correlation between Metastasis V and clinical factors

The demographic characteristics of patients and the pathologic features of tumors with Metastasis V are shown in Table 3. There was no significant difference in age, gender, tumor size, and tumor location (P > 0.05). Metastasis V was more likely to occur in poorly differentiated tumor (5/11; 45.5%) than moderately (8/46; 17.4%) and well-differentiated one (1/6; 16.7%). The Metastasis V in N2 stage (9/14; 64.3%) was more frequent than that in the N0 stage (3/35; 8.6%) or N1 stages (2/14; 14.3%). In addition, Metastasis V was positively related to the tumor invasive depth (T1: 0/1, 0%; T2: 1/12, 8.3%; T3: 7/39, 17.9%; T4: 6/11, 54.5%).
Table 3

Comparison between Metastasis V-positive patients and Metastasis V- negative patients

ParametersMetastasis V
P value
NegativePositive
Age (yr)NS
< 4583
≥ 45 and ≤ 59198
≥ 60223
Cancer size (cm)NS
≤ 32410
> 3 and < 5142
≥ 5112
GenderNS
Female196
Male308
Cancer locationNS
Colon92
Rectum4012
Differentiated gradeNS
Well51
Moderately388
Poorly65
Affected lymph nodes< 0.05
N0323
N1122
N259
Invasive depth< 0.05
T110
T2111
T3327
T456
Comparison between Metastasis V-positive patients and Metastasis V- negative patients

Correlation between Metastasis V and preoperative CEA levels

Previous studies have demonstrated the correlation between increased preoperative CEA and the poor prognosis of rectal cancer patients[10,11]. Here, we further determined the correlation between Metastasis V and preoperative CEA levels. Totally 42 CRC patients who underwent operations in our department were retrospectively studied. Metastasis V was detected in nine patients according to the pathological reports. Six patients were excluded because their preoperative CEA data was missed. The CEA levels were divided into two grades. The CEA levels more than 3 times of normal range (15.00 ng/mL) were classified as high grade, while those less than that were designated as low grade. Our data indicated that preoperative serum CEA levels in Metastasis V-positive patients were significantly higher than in Metastasis V-negative patients (4.27 ng/mL vs 3.00 ng/mL) (Table 4).
Table 4

Comparison of preoperative CEA levels between Metastasis V-positive and Metastasis V-negative patients

ParametersMetastasis V
P value
NegativePositive
Median (ng/mL)34.27< 0.05
Grade< 0.05
High (> 15.00 ng/mL)55
Low (≤ 15.00 ng/mL)7316
Comparison of preoperative CEA levels between Metastasis V-positive and Metastasis V-negative patients

DISCUSSION

In this study, we have shown that metastatic cancer cells can reside in the mesentery of the colorectum of CRC patients. These tumor cells showed no direct attachment to the primary lesions, with no involvement of vessel-lymphatic drainage system, and are confined to the fatty tissues enveloped by the fascia proper (Figure 1). In our previous study, we proposed a novel type of tumor metastasis designated as Metastasis V in gastric cancer patients[8]. Thus, we believe that Metastasis V could be detected in the mesenteries of both gastric and CRC patients. Similar to our previous studies, the incidence of Metastasis V was closely related to the tumor invasion of CRC patients, which was mainly detected in the T3 and T4 tumors (Table 2). Metastasis V was also correlated with lymphatic metastasis. Lymphatic nodes staging N1-N3 had larger percentages of Metastasis V than N0 (Table 2). Therefore, immunohistochemical analysis of Metastasis V in these patients is strongly recommended in clinical practice. More interestingly, the preoperative serum CEA levels in Metastasis V-positive patients were significantly higher than in Metastasis V-negative patients (4.27 ng/mL vs 3.00 ng/mL) (Table 4). These data indicated that the prognosis of the patients with Metastasis V-positive tumors was worse than that of patients with Metastasis V-negative tumors. Due to the limited number of patients in the current study, a larger sample of cohort study should be enrolled for further analysis. Little is known about the exact route or mechanism of Metastasis V. It was hypothesized that primary tumor lesions penetrates the intestinal wall, and then the cancer cells could probably scatter into the fatty tissues enveloped by proper fascia. In this way, Metastasis V occurs not only in CRC and gastric cancers, but also in oral head-neck, pancreas and papilla of Vater tumors[12-20]. It has been well known in practice that radical surgery for cancers should include en bloc resections of the primary tumor and neighboring tissues. However, it is difficult to determine the exact boundaries of en bloc resection within gastrointestinal tumors. “TME” or “CME” can reduce the tumor recurrence and increase patient survival, however, the possible reason is still unknown. In our opinion, the mesenteries of colorectum enveloped by the proper fascia not only propose a precise boundary for resection, but also function as pathologic barriers of Metastasis V spreading. Thus, our findings are clinically significant because TME or CME should be a useful choice for surgical excision of Metastasis V. Further studies on the efficiency of Metastasis V excision via TME or CME will be investigated.

ACKNOWLEDGMENTS

We thank Drs. Chao-Ran Yu and Jie Shen for their helpful discussion and paper revision work.

COMMENTS

Background

Local-regional recurrence of colorectal cancer (CRC) is still often noted in the patients who received radical R0-resection with no lymph-node metastasis.

Research frontiers

In addition to the classical four metastatic patterns, the existence of metastatic cancer cells in the mesentery of colorectum has also been reported, and this type of metastasis was named as “extra-capsular spreads” or “extra-nodal metastasis”. Examination of the clinical and oncological significance of isolated tumor cells found in mesentery of colorectum in CRC patients is one of the main frontiers in surgical oncology.

Innovations and breakthroughs

Metastasis V is defined as the appearance of cancer cells in the mesogastrium, and may be a risk factor for the poor prognosis after radical surgery. This study demonstrated that Metastasis V was also detected in the mesentery of colorectum, and it might be associated with the poor prognosis of CRC.

Applications

It is clinically useful to be assisted in evaluation of prognosis of CRC patients.

Peer-review

In this paper, the authors well described an interesting study about isolated cancer cells in the mesentery of colorectum (named as Metastasis V). This is an interesting point, and the issue of metastasis in patients with CRC is of main importance.
  20 in total

1.  Cervical lymph node metastasis in oral cancer: the importance of even microscopic extracapsular spread.

Authors:  J A Woolgar; S N Rogers; D Lowe; J S Brown; E D Vaughan
Journal:  Oral Oncol       Date:  2003-02       Impact factor: 5.337

2.  Extracapsular spread of squamous cell carcinoma in neck lymph nodes: prognostic factor of laryngeal cancer.

Authors:  H Hirabayashi; K Koshii; K Uno; H Ohgaki; Y Nakasone; T Fujisawa; N Syouno; T Hinohara; K Hirabayashi
Journal:  Laryngoscope       Date:  1991-05       Impact factor: 3.325

3.  CEA and CA 19-9 are still valuable markers for the prognosis of colorectal and gastric cancer patients.

Authors:  Abdullah Sisik; Mustafa Kaya; Gurhan Bas; Fatih Basak; Orhan Alimoglu
Journal:  Asian Pac J Cancer Prev       Date:  2013

4.  Extranodal metastasis is an indicator of poor prognosis in patients with gastric carcinoma.

Authors:  T Etoh; M Sasako; K Ishikawa; H Katai; T Sano; T Shimoda
Journal:  Br J Surg       Date:  2006-03       Impact factor: 6.939

Review 5.  Extranodal Extension of Nodal Metastases Is a Poor Prognostic Indicator in Gastric Cancer: a Systematic Review and Meta-analysis.

Authors:  Nicola Veronese; Matteo Fassan; Laura D Wood; Brendon Stubbs; Marco Solmi; Paola Capelli; Antonio Pea; Alessia Nottegar; Giuseppe Sergi; Enzo Manzato; Sara Carraro; Marco Maruzzo; Ivana Cataldo; Fabio Bagante; Mattia Barbareschi; Liang Cheng; Maria Bencivenga; Giovanni de Manzoni; Claudio Luchini
Journal:  J Gastrointest Surg       Date:  2016-07-13       Impact factor: 3.452

6.  Prognostic value of preoperative CEA and CA 19-9 levels in patients with colorectal cancer.

Authors:  Murat Basbug; Zulfu Arikanoglu; Nurullah Bulbuller; Ziya Cetinkaya; Erhan Aygen; Sami Akbulut; Omer Satici
Journal:  Hepatogastroenterology       Date:  2011 Mar-Apr

7.  Incidence and patterns of late recurrences in colon cancer patients.

Authors:  Anne-Marie Bouvier; Guy Launoy; Véronique Bouvier; Fabien Rollot; Sylvain Manfredi; Jean Faivre; Vanessa Cottet; Valérie Jooste
Journal:  Int J Cancer       Date:  2015-05-06       Impact factor: 7.396

8.  The extracapsular spread of tumors in cervical node metastasis.

Authors:  J T Johnson; E L Barnes; E N Myers; V L Schramm; D Borochovitz; B A Sigler
Journal:  Arch Otolaryngol       Date:  1981-12

Review 9.  Extranodal extension in N1-adenocarcinoma of the pancreas and papilla of Vater: a systematic review and meta-analysis of its prognostic significance.

Authors:  Claudio Luchini; Nicola Veronese; Antonio Pea; Giuseppe Sergi; Enzo Manzato; Alessia Nottegar; Marco Solmi; Paola Capelli; Aldo Scarpa
Journal:  Eur J Gastroenterol Hepatol       Date:  2016-02       Impact factor: 2.566

10.  The mesorectum in rectal cancer surgery--the clue to pelvic recurrence?

Authors:  R J Heald; E M Husband; R D Ryall
Journal:  Br J Surg       Date:  1982-10       Impact factor: 6.939

View more
  5 in total

1.  FANCF hypomethylation is associated with colorectal cancer in Han Chinese.

Authors:  Hang Yu; Ranran Pan; Tong Gao; Dongping Wu; Jieer Ying; Shiwei Duan
Journal:  Turk J Gastroenterol       Date:  2020-08       Impact factor: 1.852

Review 2.  Complete mesocolic excision versus conventional hemicolectomy in patients with right colon cancer: a systematic review and meta-analysis.

Authors:  Ottavia De Simoni; Andrea Barina; Antonio Sommariva; Marco Tonello; Mario Gruppo; Genny Mattara; Antonio Toniato; Pierluigi Pilati; Boris Franzato
Journal:  Int J Colorectal Dis       Date:  2020-11-10       Impact factor: 2.571

3.  Inhibition of breast cancer growth via miR-7 suppressing ALDH1A3 activity concomitant with decreasing breast cancer stem cell subpopulation.

Authors:  Meng Pan; Miao Li; Chengzhong You; Fengshu Zhao; Mei Guo; Hui Xu; Luoyang Li; Ling Wang; Jun Dou
Journal:  J Cell Physiol       Date:  2019-07-25       Impact factor: 6.384

4.  Fibrotic Phenotype of Peritumour Mesenteric Adipose Tissue in Human Colon Cancer: A Potential Hallmark of Metastatic Properties.

Authors:  Maria Tabuso; Raghu Adya; Richard Stark; Kishore Gopalakrishnan; Yee Wah Tsang; Sean James; Andrew White; Adrian Fisk; Federica Dimitri; Mark Christian; Ramesh Pulendran Arasaradnam
Journal:  Int J Mol Sci       Date:  2021-02-28       Impact factor: 5.923

5.  The Clinical Significance of Mesenteric Lymphocytes in Human Colorectal Cancer.

Authors:  Zi-Xin Wu; Fei Wang; Liang Li; Yuan Yao; Jie Long; Qing-Qing Luo; Zhi-Bin Zhao; Wang-Lin Li; Jie Cao; Zhe-Xiong Lian
Journal:  Front Oncol       Date:  2021-09-16       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.